

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

MTA Follicular lymphoma - rituximab (review of TA110)

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

Consultation

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how? |
| No issues were identified during scoping |

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these? |
| No issues were identified |

- | |
|--|
| 3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these? |
| No issues were identified |

- | |
|---|
| 4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group? |
| No |

5. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 4, or otherwise fulfil NICE's obligations to promote equality?

N/A

6. Have the Committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

N/A

Approved by Associate Director (name): Frances Sutcliffe

Date: 25 August 2011

Final appraisal determination

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

Yes. During consultation, comments were received which suggested that the draft recommendations could disadvantage older patients or those with lower performance status and they suggested that the addition of rituximab to chlorambucil would be of benefit to some of these patients. The Committee discussed the addition of rituximab to chlorambucil in the second committee meeting and the recommendations have been amended to include rituximab plus chlorambucil.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?

No, the revised recommendations will not make it more difficult for a specific group to access the technology.

3. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 2, or otherwise fulfil NICE's obligations to promote equality?

N/A

4. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

Yes, the consultation comments were described in section 4.3.

Approved by Centre or Programme Director (name): Meindert Boysen

Date: 24 November 2011